Search Results - "Kahn, James O."

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults by BARDITCH-CROVO, Patricia, DEEKS, Steven G, MCGOWAN, I. A. N, LIETMAN, Paul S, COLLIER, A. N. N, SAFRIN, Sharon, COAKLEY, Dion F, MILLER, Michael, KEARNEY, Brian P, COLEMAN, Rebecca L, LAMY, Patrick D, KAHN, James O

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care by Muñoz, Monica A, Liu, Wei, Delaney, Joseph A.C, Brown, Elizabeth, Mugavero, Michael J, Mathews, W Chris, Napravnik, Sonia, Willig, James H, Eron, Joseph J, Hunt, Peter W, Kahn, James O, Saag, Michael S, Kitahata, Mari M, Crane, Heidi M

“…OBJECTIVE:The goal of this study was to compare the effectiveness of fish oil, fenofibrate, gemfibrozil, and atorvastatin on reducing triglyceride (TG) levels…”
Get full text

Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors by Hecht, Frederick M, Grant, Robert M, Petropoulos, Christos J, Dillon, Beth, Chesney, Margaret A, Tian, Huan, Hellmann, Nicholas S, Bandrapalli, Nirmala I, Digilio, Laura, Branson, Bernard, Kahn, James O

“…Combination treatments with agents that inhibit protease and reverse transcriptase of human immunodeficiency virus type 1 (HIV-1) decrease mortality and slow…”
Get full text

Feasibility of Postexposure Prophylaxis (PEP) against Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: The San Francisco PEP Study by Kahn, James O., Martin, Jeffrey N., Roland, Michelle E., Bamberger, Joshua D., Chesney, Margaret, Chambers, Donald, Franses, Karena, Coates, Thomas J., Katz, Mitchell H.

“…The feasibility of providing postexposure prophylaxis (PEP) after sexual or injection drug use exposures to human immunodeficiency virus (HIV) was evaluated…”
Get full text

Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults by DEEKS, S. G, BARDITCH-CROVO, P, LIETMAN, P. S, HWANG, F, CUNDY, K. C, ROONEY, J. F, HELLMANN, N. S, SAFRIN, S, KAHN, J. O

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load by Deeks, Steven G., Kitchen, Christina M.R., Liu, Lea, Guo, Hua, Gascon, Ron, Narváez, Amy B., Hunt, Peter, Martin, Jeffrey N., Kahn, James O., Levy, Jay, McGrath, Michael S., Hecht, Frederick M.

“…Although generalized T-cell activation is an important factor in chronic HIV disease pathogenesis, its role in primary infection remains poorly defined. To…”
Get full text

Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems by Kitahata, Mari M, Rodriguez, Benigno, Haubrich, Richard, Boswell, Stephen, Mathews, W Christopher, Lederman, Michael M, Lober, William B, Van Rompaey, Stephen E, Crane, Heidi M, Moore, Richard D, Bertram, Michael, Kahn, James O, Saag, Michael S

Get full text

Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons by Grant, Robert M, Hecht, Frederick M, Warmerdam, Maria, Liu, Lea, Liegler, Teri, Petropoulos, Christos J, Hellmann, Nicholas S, Chesney, Margaret, Busch, Michael P, Kahn, James O

“…CONTEXT Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy. OBJECTIVE…”
Get full text

Acute Human Immunodeficiency Virus Type 1 Infection by Kahn, James O, Walker, Bruce D

“…Acute human immunodeficiency virus type 1 (HIV-1) infection is a transient symptomatic illness associated with high-titer HIV-1 replication and a robust and…”
Get full text

The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels Among HIV-Infected Patients Entering Care With a CD4 Count Greater Than 500/μL, in a Public Health Setting by Geng, Elvin H., Hare, C. Bradley, Kahn, James O., Jain, Vivek, Van Nunnery, Tracy, Christopoulos, Katerina A., Deeks, Steven G., Gandhi, Monica, Havlir, Diane V.

“…Background. On 1 January 2010, a large, publicly funded clinic in San Francisco announced a "universal ART" approach to initiate antiretroviral therapy (ART)…”
Get full text

Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection by ALTFELD, Marcus, ADDO, Marylyn M, ALLEN, Todd M, FEENEY, Margaret E, KAHN, James O, SEKALY, Rafick P, LEVY, Jay A, ROCKSTROH, Jürgen K, GOULDER, Philip J. R, WALKER, Bruce D, ROSENBERG, Eric S, HECHT, Frederick M, LEE, Paul K, VOGEL, Martin, YU, Xu G, DRAENERT, Rika, JOHNSTON, Mary N, STRICK, Daryld

“…HLA-B57, as well as cytotoxic T-lymphocyte (CTL) responses restricted by this allele, have been strongly associated with long-term non-progressive chronic…”
Get full text

Use of laboratory tests and clinical symptoms for identification of primary HIV infection by HECHT, Frederick M, BUSCH, Michael P, RAWAL, Bhupat, WEBB, Marcy, ROSENBERG, Eric, SWANSON, Melinda, CHESNEY, Margaret, ANDERSON, Jennifer, LEVY, Jay, KAHN, James O

“…To determine the sensitivity and specificity of symptoms, three HIV-1 RNA assays, a p24 antigen EIA and a third-generation enzyme immunoassay (EIA) antibody…”
Get full text

HIV RNA Testing in the Context of Nonoccupational Postexposure Prophylaxis by Roland, Michelle E., Elbeik, Tarek A., Kahn, James O., Bamberger, Joshua D., Coates, Thomas J., Krone, Melissa R., Katz, Mitchell H., Busch, Michael P., Martin, Jeffrey N.

“…Background. The specificity and positive predictive value of human immunodeficiency virus (HIV) RNA assays have not been evaluated in the setting of…”
Get full text

Postexposure Prophylaxis for Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: Identification and Characterization of the Source of Exposure by Roland, Michelle E., Martin, Jeffrey N., Grant, Robert M., Hellmann, Nicholas S., Bamberger, Joshua D., Katz, Mitchell H., Chesney, Margaret, Franses, Karena, Coates, Thomas J., Kahn, James O.

“…In a nonrandomized study of nonoccupational postexposure prophylaxis (PEP), a cross-sectional evaluation of subjects who were the source of human…”
Get full text

Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV by Roland, Michelle E., Neilands, Torsten B., Krone, Melissa R., Katz, Mitchell H., Franses, Karena, Grant, Robert M., Busch, Michael P., Hecht, Frederick M., Shacklett, Barbara L., Kahn, James O., Bamberger, Joshua D., Coates, Thomas J., Chesney, Margaret A., Martin, Jeffrey N.

“…Background. The efficacy of antiretroviral postexposure prophylaxis (PEP) against infection with human immunodeficiency virus (HIV) following occupational…”
Get full text

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection by Altfeld, M, Rosenberg, E S, Shankarappa, R, Mukherjee, J S, Hecht, F M, Eldridge, R L, Addo, M M, Poon, S H, Phillips, M N, Robbins, G K, Sax, P E, Boswell, S, Kahn, J O, Brander, C, Goulder, P J, Levy, J A, Mullins, J I, Walker, B D

“…Immune responses induced during the early stages of chronic viral infections are thought to influence disease outcome. Using HIV as a model, we examined…”
Get full text

Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial by Kahn, J O, Cherng, D W, Mayer, K, Murray, H, Lagakos, S

“…Despite enormous improvements achieved through the use of antiretroviral therapies (ARTs), the risk for eventual human immunodeficiency virus (HIV) disease…”
Get full text

Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior by MARTIN, Jeffrey N, ROLAND, Michelle E, KATZ, Mitchell H, NEILANDS, Torsten B, KRONE, Melissa R, BAMBERGER, Joshua D, KOHN, Robert P, CHESNEY, Margaret A, FRANSES, Karena, KAHN, James O, COATES, Thomas J

“…The effectiveness of postexposure prophylaxis (PEP) following occupational exposure to HIV has prompted advocacy for PEP following sexual or drug-use…”
Get full text

New Testing Strategy to Detect Early HIV-1 Infection for Use in Incidence Estimates and for Clinical and Prevention Purposes by Janssen, Robert S, Satten, Glen A, Stramer, Susan L, Rawal, Bhupat D, O'Brien, Thomas R, Weiblen, Barbara J, Hecht, Frederick M, Jack, Noreen, Cleghorn, Farley R, Kahn, James O, Chesney, Margaret A, Busch, Michael P

“…CONTEXT.— Differentiating individuals with early human immunodeficiency virus 1 (HIV-1) infection from those infected for longer periods is difficult but…”
Get full text

Higher CD4+ T Cell Counts Associated with Low Viral pol Replication Capacity among Treatment-Naive Adults in Early HIV-1 Infection by Barbour, Jason D, Hecht, Frederick M, Wrin, Terri, Segal, Mark R, Ramstead, Clarissa A, Liegler, Teri J, Bursch, Michael P, Petropoulos, Christos J, Hellmann, Nicholas S, Kahn, James O, Grant, Robert M

“…Background. Infection with primary drug-resistant human immunodeficiency virus type 1 (HIV-1) has been associated with higher CD4+ T cell counts in drug-naive…”
Get full text